GlassScriptPhysician profile
Arthur Y Chow
NPI 1982604005
$1,241.97
in general payments reported to CMS, 2019-2025
19 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $99.34 · 2022: $23.08 · 2023: $148 · 2024: $447 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $202.19 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Atricure, INC. | $151.65 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atricure Cryoice Cryosphere Cryoablation System, Atriclip Laa Exclusion System |
| Novartis Pharmaceuticals Corporation | $132.33 | 2019-2025 | |
| Abbott Laboratories | $130.59 | 2020-2024 | Amplatzer Talisman, Amplatzer Amulet |
| Baxter Healthcare | $90.49 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.16 | 2019-2024 | Lifevest |
| Amgen INC. | $80.24 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $63.43 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $61.04 | 2020-2024 | Farxiga |
| Heartflow, INC. | $46.66 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.27 | 2025 | Camzyos |
| Edwards Lifesciences Corporation | $41.03 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sanofi-Aventis U.S. LLC | $28.35 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $25.61 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.54 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $16.67 | 2019 | |
| Davol INC. | $15.28 | 2025 | Arista |
| Pfizer INC. | $12.44 | 2019 | |
| Bardy Diagnostics, INC. | $2.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.